恶性肿瘤化疗后D-二聚体与预后相关性的临床研究  

Prognosis of malignant tumor after chemotherapy D-dimer and correlation of clinical research

作　　者：李秀翠[1] 赵成[1] 姜维美[1] 胡春霞[1] 

机构地区：[1]连云港市第二人民医院,江苏连云港222000

出　　处：《基层医学论坛》2017年第35期4912-4914,共3页The Medical Forum

摘　　要：目的探讨恶性肿瘤化疗后D-二聚体的变化情况及与预后的相关性。方法所有入组患者于化疗前和化疗4个周期后(约84 d后)分别按照试剂盒说明书采集标本,采用免疫比浊法测定血浆中D-二聚体含量;根据患者化疗后效果评价,比较肿瘤转移患者及未转移患者D-二聚体的差异;将患者进行分组(CR+PR组及SD+PD组),比较治疗前后D-二聚体水平。结果肿瘤转移患者血浆D-二聚体较未转移患者高;化疗前所有患者D-二聚体平均为(0.983±0.093)mg/L,化疗后为(0.836±0.094)mg/L,差异无统计学意义(P>0.05);化疗后CR+PR组D-二聚体为(0.507±0.072)mg/L,SD+PD组化疗后为(1.229±0.195)mg/L,与本组化疗前比较差异均有统计学意义(P<0.05)。结论化疗后预后尚可患者D-二聚体水平较低,预后欠佳的患者D-二聚体水平较高,其可在一定程度上预测或评估患者的病情变化。Objective To investigate the relationship between the changes of D-dimer and the prognosis of malignant tumor after chemotherapy. Methods All patients before chemotherapy and after 4 cycles of chemotherapy （about 84 days） respectively according to the kit to collect specimens,D-dimer was measured by Turbidimetric inhibition immuno assay of all patients. According to the effect of patients after chemotherapy, the difference of D-dimer between tumor metastasis and non metastasis patients;patients were grouped （CR＋PR group and SD＋PD group）, and D-dimer was calculated before and after chemotherapy respectively,and compared between the groups.Results D-dimer of patients with no tumor metastasis was higher in patients with metastases. D-dimer of patients before chemotherapy was （0.983 ±0.093） mg/L,and （0.836 ±0.094）mg/L after chemotherapy,the difference was not statistically significant. D-dimer of ＊The prognosis of the patients after chemotherapy is poor, and the D-dimer was high. Conclusion By observing the results of D-dimer, the patient＇s condition can be predicted and evaluated to a certain extent.

关 键 词：恶性肿瘤 化疗 D-二聚体 预后 相关性 

分 类 号：R730.53[医药卫生—肿瘤]